← 返回

IL-12 纳米伴侣工程化 CAR-T 细胞用于强效肿瘤免疫治疗

英文原题:IL-12 nanochaperone-engineered CAR T cell for robust tumor-immunotherapy.

查看英文原题

IL-12 nanochaperone-engineered CAR T cell for robust tumor-immunotherapy.

PubMed 2021/12/29(内容时间) Biomaterials Q1 · IF 13.6(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

尽管CAR-T(CAR-T)细胞免疫疗法在临床已取得显著成功,但由于免疫抑制性肿瘤微环境中活化T细胞浸润不足,其对实体瘤的治疗效果仍有限。本文开发了经IL-12纳米刺激物工程化改造的CAR-T 细胞生物杂合体(INS-CAR-T),通过免疫反馈增强CAR-T 细胞抗肿瘤免疫。作为刺激性纳米伴侣,负载IL-12的人血清白蛋白(HSA)纳米颗粒可通过生物正交化学有效偶联至CAR-T 细胞,且不影响其抗肿瘤能力。肿瘤抗原触发细胞表面巯基增多后,INS-CAR-T 生物杂合体会应答性释放IL-12。释放出的IL-12反过来明显促进CCL5、CCL2和CXCL10分泌,进一步选择性募集并扩增肿瘤中的CD8+ CAR-T 细胞。最终,IL-12纳米伴侣的免疫增强作用显著提高CAR-T 细胞抗肿瘤能力,大幅清除实体瘤并最大程度减少不良副作用。

因此,具有免疫反馈功能的INS-CAR-T 生物杂合体中,INS作为智能“纳米伴侣”,有望成为高效且安全抗肿瘤免疫治疗的有力工具。

展开英文摘要原文

Although chimeric antigen receptor T (CAR T) cell immunotherapy has demonstrated remarkable success in clinical, therapeutic effects are still limited in solid tumor due to lack of activated T cell infiltration in immunosuppression of tumor microenvironment.

Herein, we develop IL-12 nanostimulant-engineered CAR T cell (INS-CAR T) biohybrids for boosting antitumor immunity of CAR T cells via immunofeedback. As stimulating nanochaperone, IL-12-loaded human serum albumin (HSA) nanoparticles are effectively conjugated onto CAR T cells via bioorthogonal chemistry without influencing their antitumor capabilities. IL-12 is responsively released from INS-CAR T biohybrids in presence of the increased thiol groups on cell-surface triggered by tumor antigens.

In return, released IL-12 obviously promotes the secretion of CCL5, CCL2 and CXCL10, which further selectively recruits and expands CD8 + CAR T cells in tumors. Ultimately, the immune-enhancing effects of IL-12 nanochaperone significantly boost CAR T cell antitumor capabilities, dramatically eliminated solid tumor and minimized unwanted side effects. Hence, immunofeedback INS-CAR T biohybrids, which include INS that serves as an intelligent 'nanochaperone', could provide a powerful tool for efficient and safe antitumor immunotherapy.

论文信息

作者
Luo Y、Chen Z、Sun M、Li B、Pan F、Ma A、Liao J、Yin T
第一作者单位
Guangdong Key Laboratory of Nanomedicine, CAS Key Laboratory of Health Informatics, CAS-HK Joint Lab of Biomaterials, Shenzhen Institutes of Advanced Technology (SIAT), Chinese Academy of Sciences, Shenzhen, 518055, PR China; Key Laboratory for Nanomedicine, Department of Histology and Embryology and School of Pharmacy, Guangdong Medical University, Dongguan, 523808, PR China.China
通讯作者单位
Guangdong Key Laboratory of Nanomedicine, CAS Key Laboratory of Health Informatics, CAS-HK Joint Lab of Biomaterials, Shenzhen Institutes of Advanced Technology (SIAT), Chinese Academy of Sciences, Shenzhen, 518055, PR China; Zhuhai Institute of Advanced Technology Chinese Academy of Sciences, 519000, Zhuhai, PR China. Electronic address: lt.cai@siat.ac.cn.China
文献类型
非美国政府资助研究
期刊
Biomaterials2022 Feb
原文标识
PubMed 34995901 · DOI 10.1016/j.biomaterials.2021.121341